These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 3991533)

  • 1. Assessing the benefit of changing aluminium hydroxide schedule on anaemia and serum phosphorus control.
    Cannata JB; Suarez Suarez C; Rogrigues Suarez C; Cuesta V; Sanz-Medel A; Peral V; Herrera J
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():410-4. PubMed ID: 3991533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of aluminium hydroxide intake on haemoglobin concentrations and blood transfusion requirements in haemodialysis patients.
    Cannata JB; Ruiz Alegria P; Cuesta MV; Herrera J; Peral V
    Proc Eur Dial Transplant Assoc; 1983; 20():719-24. PubMed ID: 6657691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum].
    Demontis R; Reissi D; Noël C; Morinière P; Renaud H; Leflon P; Westeel PF; Brasseur J; Coevoet B; Fournier A
    Nephrologie; 1988; 9(3):135-8. PubMed ID: 3194044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal aluminium absorption: is it modulated by the iron-absorptive mechanism?
    Cannata JB; Suarez Suarez C; Cuesta V; Rodriguez Roza R; Allende MT; Herrera J; Perez Llanderal J
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():354-9. PubMed ID: 3991522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Magnesium hydroxide treatment of hyperphosphatemia in chronic hemodialysis patients with an aluminum overload].
    Roujouleh H; Lavaud S; Toupance O; Melin JP; Chanard J
    Nephrologie; 1987; 8(2):45-50. PubMed ID: 3614505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
    Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
    Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of high serum aluminium in a patient on maintenance haemodialysis.
    Wallace MR
    N Z Med J; 1981 May; 93(684):335-7. PubMed ID: 6942294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1 alpha OH vitamin D3 increases plasma aluminium in haemodialysed patients taking Al (OH)3.
    Fournier A; Demontis R; Tahiri Y; Herve M; Moriniere P; Leflon A; Abdull-Massih Z; Atik H; Benelmouffok S
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():390-4. PubMed ID: 3991529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevalence of histological types of bone disease in a hemodialysis center limiting the oral intake of aluminum hydroxide].
    Belbrik S; Marie A; Boudailliez B; Morinière P; Sébert JL; Solal MC; Westeel PF; Roche D; Fournier A
    Nephrologie; 1990; 11(2):83-90. PubMed ID: 2392208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum.
    Morinière P; Cohen-Solal M; Belbrik S; Boudailliez B; Marie A; Westeel PF; Renaud H; Fievet P; Lalau JD; Sebert JL
    Nephron; 1989; 53(2):93-101. PubMed ID: 2812179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aluminum hydroxide: evaluation of two dosage forms and two dosing schedules in reducing intestinal phosphate absorption.
    Smith DR; Chang BS; Johnson CE
    Am J Hosp Pharm; 1978 Jan; 35(1):58-61. PubMed ID: 623119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era].
    Arenas MD; Malek T; Gil MT; Moledous A; Núñez C; Alvarez-Ude F
    Nefrologia; 2008; 28(2):168-73. PubMed ID: 18454706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.